Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.

International immunopharmacology - 1 Oct 2020

Wang Yejinpeng, Chen Liang, Ju Lingao, Xiao Yu, Wang Xinghuan

Abstract excerpt

BACKGROUND: Immunotherapy has made encouraging progress in the treatment of urothelial carcinoma, but only a small percentage of patients respond effectively to the immune checkpoint blockade (ICB). Our study aims to develop a classifier could effectively predict the response to ICB. METHODS: Support vector machines recursive feature elimination (SVM-RFE) algorithm was used to feature selection, then compared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Datasets as Topic

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Machine Learning

Share to Urinary Bladder Neoplasms

Share to Urothelium

Source

Identifiers

PMID: 32738594
DOI: 10.1016/j.intimp.2020.106818

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.PMID 32738594Read ↗

Risk stratification based on immune signature and prediction of immune checkpoint inhibitor’s efficacy for bladder urothelial carcinomaSemantic proximity Read ↗

Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysisSemantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.Semantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypesSemantic proximity Read ↗

Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study.Semantic proximity Read ↗

Identification of an immunotherapy-responsive molecular subtype of bladder cancer.Semantic proximity Read ↗

An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohortsSemantic proximity Read ↗

Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA)Semantic proximity Read ↗

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.Semantic proximity Read ↗

Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and in vitro validationSemantic proximity Read ↗

Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma.Semantic proximity Read ↗

Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.